

For immediate release

Sumitomo Chemical to Sell Entire Stake in AstraZeneca K.K.

TOKYO, February 28, 2014 -- Sumitomo Chemical announced that it has decided to sell its entire stake in AstraZeneca K.K. to AstraZeneca UK LIMITED. After the transfer, Sumitomo Chemical will no longer be a shareholder of AstraZeneca K.K..

The sale of the entire equity holding in AstraZeneca K.K. aims to further strengthen the financial base of Sumitomo Chemical.

Overview of AstraZeneca K.K.

1. Name: AstraZeneca K.K. Japan
2. President: Gabriel Baertschi
3. Headquarters: Osaka, Japan
4. Founded: April 11, 1975
5. Business: Development, manufacturing and marketing of ethical pharmaceuticals
6. Accounting term: December 31st every year
7. Capital: 2 billion yen
8. Shareholding ratio: AstraZeneca Continent B.V. 80%
Sumitomo Chemical Co., Ltd 20%

Impact of the transaction on financial forecast for the year ending March 31, 2014

From the stock sale, Sumitomo Chemical is expected to post an extraordinary gain of approximately 10 billion yen on a non-consolidated basis. There will be no effect on Sumitomo Chemical's consolidated financial results as Sumitomo Chemical has recognized its equity in earnings of affiliates over a period of holding AstraZeneca K.K. shares.

###